Waldencast has received FDA approval for Obagi saypha MagIQ, an injectable hyaluronic acid gel under the Obagi Medical brand. This marks the company's entry into the U.S. HA dermal filler market.

The intradermal gel product is developed by Croma-Pharma GmbH of Leobendorf, Austria, and brought to the U.S. through its strategic partner Waldencast plc under the Obagi Medical brand. It utilizes Croma-Pharma’s proprietary MACRO Core Technology to create a stable 3D HA matrix for natural-looking results.

Approval comes after Croma's U.S. trial for nasolabial fold correction in a randomized, evaluator-blinded, active-controlled, multicenter trial that enrolled 270 patients of all Fitzpatrick Skin Types over 48 weeks. It confirmed non-inferiority and similar safety profiles compared to the FDA approved control product. 

Commercial launch is planned for 2026, in a U.S. rollout that also plans to include saypha ChIQ, which is under FDA review.

Waldencast plc acquired Novaestiq Corp. and the U.S. rights to the Saypha line of hyaluronic acid injectable gels in July 2025, expanding Obagi Medical's product offerings in the aesthetics market beyond medical-grade skincare.